Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

25.91 +1.41 (+5.76%)

Delayed Quote Updated: 3:39 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage ↗

July 18, 2022

Via Benzinga

Hold Pfizer Today With Catalysts for Further Growth Tomorrow

July 18, 2022

Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.

Via MarketBeat

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success ↗

June 17, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

Expert Ratings For Beam Therapeutics ↗

January 10, 2022

Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f...

Via Benzinga

The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol ↗

July 12, 2022

This could offer an improvement over CRISPR, which requires cutting DNA.

Via Investor's Business Daily

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics ↗

July 07, 2022

Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ:

Via Benzinga

Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗

July 05, 2022

The FDA's advisors recently backed Pfizer's Covid shot for young children.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock? ↗

January 13, 2022

How the pandemic continued a transformation Pfizer says began years ago.

Via Investor's Business Daily

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs ↗

January 10, 2022

Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ...

Via Benzinga

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

January 10, 2022

From Pfizer Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗

January 05, 2022

Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:

Via Benzinga

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

Got $1,000? Check Out These 3 Top Biotech Stocks ↗

December 03, 2021

Two big biotechs and one smaller one that could be winners over the long term.

Via The Motley Fool

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing ↗

November 12, 2021

Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...

Via Benzinga

Cathie Wood's Buying Beam Therapeutics -- Should You? ↗

November 09, 2021

Can this high-flying gene-editing stock keep on climbing for new investors?

Via The Motley Fool

Looking Into Beam Therapeutics's Return On Capital Employed ↗

November 08, 2021

Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a...

Via Benzinga

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology ↗

October 19, 2021

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.